Having just raised $148m to advance its mid-stage gene therapy for eye diseases, the UK's Gyroscope Therapeutics Limited has declared its intentions to seek a listing on the US NASDAQ.
The London-headquartered company has completed the sizeable series C financing led by Forbion and investors including Sofinnova, Tetragon, Fosun Pharma,...